The California Stem Cell Report

Share this post

User's avatar
The California Stem Cell Report
China Targets San Diego's Illumina in Retaliation for Trump Tariffs Increase

China Targets San Diego's Illumina in Retaliation for Trump Tariffs Increase

Gene sequencing firm says it assessing the move

David Jensen's avatar
David Jensen
Mar 05, 2025
∙ Paid

Share this post

User's avatar
The California Stem Cell Report
China Targets San Diego's Illumina in Retaliation for Trump Tariffs Increase
Share
Google chart

In the wake of President Trump’s new tariffs, China retaliated this week by barring the San Diego gene-sequencing firm, Illumina, Inc., from exporting its equipment to China.

On the news, Illumina’s stock price dropped from $84.03 on Monday to $80.69 but bounced back yesterday to close at $84.89. The company, which dominates the gene sequencing market, is one of 15 American companies targeted by China for punitive trade measures. On Feb. 4, China designated it as an “unreliable entity.”

Most of the other companies that were singled out by China have little to do with biotechnology.

Illumina said in a statement that the move does not ban Illumina from operating in China.

Keep reading with a 7-day free trial

Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 David Jensen
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share